Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Hashimoto's encephalitis and sleep disorders].
Uzenot D, Suchet L, Feuillet L, Rey M, Pelletier J, Ali Cherif A. Uzenot D, et al. Among authors: suchet l. Rev Neurol (Paris). 2003 Sep;159(8-9):793-4. Rev Neurol (Paris). 2003. PMID: 13679724 French.
Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N'Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S; Société Francophone de la Sclérose en Plaques. Balloy G, et al. Among authors: suchet l. J Neurol. 2018 Oct;265(10):2251-2259. doi: 10.1007/s00415-018-8984-7. Epub 2018 Jul 27. J Neurol. 2018. PMID: 30054790
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome.
Lebrun-Frénay C, Rollot F, Mondot L, Zephir H, Louapre C, Le Page E, Durand-Dubief F, Labauge P, Bensa C, Thouvenot E, Laplaud D, de Seze J, Ciron J, Bourre B, Cabre P, Casez O, Ruet A, Mathey G, Berger E, Moreau T, Al Khedr A, Derache N, Clavelou P, Guennoc AM, Créange A, Neau JP, Tourbah A, Camdessanché JP, Maarouf A, Callier C, Vermersch P, Kantarci O, Siva A, Azevedo C, Makhani N, Cohen M, Pelletier D, Okuda D, Vukusic S; RISC, SFSEP, and OFSEP Investigators. Lebrun-Frénay C, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2128271. doi: 10.1001/jamanetworkopen.2021.28271. JAMA Netw Open. 2021. PMID: 34633424 Free PMC article.
Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.
Papeix C, Castelnovo G, Leray E, Coustans M, Levy P, Visy JM, Kobelt G, Lamy F, Allaf B, Heintzmann F, Chouette I, Raponi E, Durand B, Grevat E, Kamar D, Debouverie M, Lebrun-Frenay C; Virgile Study Group. Papeix C, et al. Neurol Ther. 2022 Jun;11(2):633-658. doi: 10.1007/s40120-022-00334-y. Epub 2022 Feb 11. Neurol Ther. 2022. PMID: 35147904 Free PMC article.
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.
Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC; GAP Study Group. Devonshire V, et al. Among authors: suchet l. Eur J Neurol. 2011 Jan;18(1):69-77. doi: 10.1111/j.1468-1331.2010.03110.x. Eur J Neurol. 2011. PMID: 20561039 Clinical Trial.
20 results